Liver disease is estimated to cause 2 million deaths each year across the world¹. With incidence rising annually, the burden on health sciences and economies will also continue to increase.
Whilst lifestyle adjustments such as a healthy diet and increased exercise are often enough to reverse the disease in its earlier stages, the signs of liver disease frequently go unnoticed until the disease has reached its later stages.
Patients that are unlucky enough to progress to stage F4 non-alcoholic steatohepatitis (NASH) or develop acute-on-chronic liver failure (ACLF) have a low chance of survival. Currently, the only way to save these patients’ lives is by replacing the damaged liver via transplantation.
Liver transplantations in the US in 2016².
Promethera® aims to help patients in need of liver transplantation, by either finding a potential alternative to transplantation, or by providing more time for those to whom a transplant is essential by potentially stabilizing their disease progression.
Using intact, living cells in a therapeutic manner has an advantage over conventional pharmaceuticals since they can provide multiple mechanisms in one treatment. This approach allows Promethera’s lead cell-therapy treatment, HepaStem™, to provide anti-fibrotic, anti-inflammatory and immunomodulatory benefits in one. Promethera® is therefore uniquely positioned among companies developing NASH treatments to develop a potential treatment for cirrhosis in late-stage NASH and ACLF.
A further benefit of Promethera®’s approach is that multiple patients could be treated with one donated liver. The end result will be that patients can be offered a less invasive treatment option, as well as reducing demand for donated livers by ensuring each is used as efficiently as possible.
DISCOVER MORE ABOUT LIVER SCIENCE AND OUR TECHNOLOGY
- Asrain SK et al. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171
- Global Observatory on Donation and Transplantation. Chart: Total liver. Accessed September 2019 via the GODT website